2024 World Conference on Lung Cancer (WCLC) - ePosters-EP.06B.20 Prognostic Impact of Nectin-like Molecule-5 (CD155) Expression in Non-Small Cell Lung Cancer

Pdf Summary

The study investigates the prognostic impact of CD155 expression in non-small cell lung cancer (NSCLC) among Latin American patients. CD155, a transmembrane protein, is known to inhibit antitumor immune responses and predicts worse prognosis in NSCLC, with expression found in 38-48% of cases. The study identifies a correlation between high CD155 expression and poorer responses to anti-PD-1 therapy. The interplay between CD155 and oncogenic driver mutations like EGFR and ALK is explored, though it remains not fully understood.<br /><br />Conducted as an observational longitudinal study, it involved 86 advanced NSCLC patients from January to October 2019. The cohort showed a female predominance (60.5%) and a high percentage of never-smokers (53.5%). CD155 expression showed no correlation with PD-L1 TPS levels. Higher CD155 levels correlated significantly with EGFR exon 19 deletions.<br /><br />The results indicated that 97.7% of the patients expressed CD155, with high expression being associated with worse median progression-free survival (mPFS) and median overall survival (mOS). For patients harboring oncogenic alterations, those in the CD155 High group had shorter mOS compared to those with low CD155 expression. In patients without genomic alterations, the CD155 High group had notably shorter mPFS and mOS. Additionally, high CD155 was associated with higher PD-L1 positivity among patients with ALK or EGFR alterations.<br /><br />In conclusion, the study suggests that high CD155 expression is a predictor of poor survival outcomes in advanced NSCLC, particularly in patients without oncogenic driver mutations, highlighting a potential target for therapeutic interventions. Among patients with EGFR alterations, CD155 expression was notably higher in cases with exon 19 deletions than with L858R mutations.

Asset Subtitle

Enrique Caballé-Pérez

Meta Tag

Speaker Enrique Caballé-Pérez

Topic Pathology and Biomarkers

Keywords

CD155 expression

non-small cell lung cancer

NSCLC

Latin American patients

anti-PD-1 therapy

oncogenic driver mutations

EGFR exon 19 deletions

progression-free survival

overall survival

therapeutic interventions